



Supplemental Figure 1. Tumor volume in control groups.



**Supplemental Figure 2. Tumor volume progression time.** (A) Tumor volume quadrupling time (TVQT) in non-treated control and treated groups calculated at the beginning of the treatment to compare the overall efficacy of all therapeutic protocols. (B) Tumor volume doubling time (TVDT) in non-treated control and treated groups calculated after RIT to estimate the benefits of a pretreatment by antiangiogenic agent.



**Supplemental Figure 3. Histological studies of TT xenograft treated by CBOP11.** (A) Hematoxylin-eosin staining showing large tumor necrosis (original magnification, x 100). (B) Immunohisto-chemistry using anti-CEA antibody. Strong CEA expression on both surface and cytoplasm (original magnification, x 200). (C) Hybridization with Ki67 antibody. 40-50% MIB-1 expression (original magnification, x 200).